Clinical Trial Update: Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of oral ixazomib in cancer patients with liver dysfunction to assess exposure and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• NINLARO (ixazomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Solid Tumors, Hematologic Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2016-03-25